Abstract #0402

gagCEST imaging in patients with breast tumors at 7 Tesla - preliminary results

Olgica Zaric¹, Katja Pinker-Domenig^2,3, Esau Poblador ¹, Vadimir Mlynarik¹, Thomas Helbich⁴, Siegfrid Trattnig^1,5, and Wolfgang Bogner¹

¹High Field Magnetic Resonance Centre, Medical University of Vienna, Vienna, Austria, ²Department of Biomedical Imaging and Image-guided Therapy, Medical University Vienna, Vienna, Austria, ³Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁴Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁵Christian Doppler Lab for Clinical Molecular MRI, Christian Doppler Forschungsgesellschaft, Vienna, Austria, Vienna, Austria

Proteoglycans content in malignant tumors may provide information regarding the altered metabolism and neoplastic cell behavior. The aim of this study was to investigate the feasibility of gagCEST imaging in patients with breast tumors at 7 Tesla. Eleven patients with 15 lesions were examined. gagCEST imaging was performed with 1.7mm in-plane resolution and nine minutes of measurement time. Results based on MTRasym showed excellent differentation between malignant and benign lesions (CI=95%, p=0.001) and insignificant difference between benign and healthy tissue (CI=95%, p=0.159). gagCEST has a great potential in breast tumors evaluations providing substantially different information obtained with standard MRI techniques.

This abstract and the presentation materials are available to members only; a login is required.

Join Here